

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

MSCV_Cas9_puro

RRID:Addgene_65655

Type: Plasmid

Proper Citation

RRID:Addgene_65655

Plasmid Information

URL: <http://www.addgene.org/65655>

Proper Citation: RRID:Addgene_65655

Insert Name: Cas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:25961408](#)

Vector Backbone Description: Backbone Marker:clontech; Backbone Size:6200; Vector Backbone:MSCV_puro; Vector Types:Mammalian Expression, Retroviral, CRISPR; Bacterial Resistance:Ampicillin

Plasmid Name: MSCV_Cas9_puro

Record Creation Time: 20220422T222413+0000

Record Last Update: 20260725T075011+0000

Ratings and Alerts

No rating or validation information has been found for MSCV_Cas9_puro.

No alerts have been found for MSCV_Cas9_puro.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Long K, et al. (2025) A clinical-stage oncology compound selectively targets drug-resistant cancers. bioRxiv : the preprint server for biology.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. Cell reports. Medicine, 5(6), 101572.

Lidström T, et al. (2023) Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer. Cancer immunology research, 11(1), 72.

Anderson R, et al. (2023) Pyruvate Dehydrogenase Inhibition Leads to Decreased Glycolysis, Increased Reliance on Gluconeogenesis and Alternative Sources of Acetyl-CoA in Acute Myeloid Leukemia. Cancers, 15(2).

Mensali N, et al. (2023) ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nature communications, 14(1), 3375.

Thandapani P, et al. (2022) Valine tRNA levels and availability regulate complex I assembly in leukaemia. Nature, 601(7893), 428.

Ghiraldeli L, et al. (2022) Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). Cancer letters, 535, 215659.

Huse K, et al. (2022) Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression. Journal of immunology (Baltimore, Md. : 1950), 209(10), 2042.

Anderson R, et al. (2022) Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature communications, 13(1), 1673.

Wang W, et al. (2022) TCF-1 promotes chromatin interactions across topologically associating domains in T cell progenitors. Nature immunology, 23(7), 1052.

Klimovich B, et al. (2022) Partial p53 reactivation is sufficient to induce cancer regression. Journal of experimental & clinical cancer research : CR, 41(1), 80.

Bai B, et al. (2020) Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology. Methods in molecular biology (Clifton, N.J.), 2115, 445.

Vatapalli R, et al. (2020) Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature communications, 11(1), 4153.

Caeser R, et al. (2019) Genetic modification of primary human B cells to model high-grade lymphoma. Nature communications, 10(1), 4543.

Connelly KE, et al. (2019) Engagement of DNA and H3K27me3 by the CBX8 chromodomain drives chromatin association. Nucleic acids research, 47(5), 2289.

Wang E, et al. (2019) Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. *Cancer cell*, 35(3), 369.

Guillamot M, et al. (2019) The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation. *Nature immunology*, 20(9), 1196.

Pardee TS, et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 24(9), 2060.

Ipsaro JJ, et al. (2017) Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. *PloS one*, 12(2), e0172177.